Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease
Authors:
- Jacqueline B. TileyJTJacqueline B. Tiley
- James J. BeaudoinJBJames J. Beaudoin
- Vimal K. DerebailVDVimal K. Derebail
- William A. MurphyWMWilliam A. Murphy
- Christine C. ParkCPChristine C. Park
- Justin A. VeederJVJustin A. Veeder
- Lana TranLTLana Tran
- Jessica L. BeersJBJessica L. Beers
- Wei JiaWJWei Jia
- Paul W. StewartPSPaul W. Stewart
- Kim L. R. BrouwerKBKim L. R. Brouwer
- 24 September 2024
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 353-364
Abstract
Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non‐clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug‐induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin‐I (CP‐I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B‐mediated DDI risk in humans. In this clinical observational cohort‐comparison study, bile acid profiles and CP‐I concentrations in healthy volunteers and patients with ADPKD were compared.Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP‐I concentrations, were quantified by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS).Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3‐fold) and taurine‐conjugated (2.8‐fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5‐, 2.9‐, 2.8‐, 1.6‐, 1.7‐ and 2.7‐fold, respectively) in patients with ADPKD. Furthermore, serum CP‐I concentrations were elevated and the renal clearance of CP‐I was reduced in patients with ADPKD compared to healthy volunteers.Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP‐I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers.Keywords
Funding Information
- National Institute of General Medical Sciences (R35 GM122576)
This publication has 53 references indexed in Scilit:
- Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate DrugsClinical Pharmacology & Therapeutics, 2023
- Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney DiseaseClinical Pharmacology & Therapeutics, 2022
- Identification of Glycochenodeoxycholate 3‐O‐Glucuronide and Glycodeoxycholate 3‐O‐Glucuronide as Highly Sensitive and Specific OATP1B1 BiomarkersClinical Pharmacology & Therapeutics, 2020
- Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan HepatotoxicityClinical Pharmacology & Therapeutics, 2020
- A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal ImpairmentClinical Pharmacology & Therapeutics, 2020
- Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveClinical Pharmacology & Therapeutics, 2018
- Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and SimulationClinical Pharmacology & Therapeutics, 2017
- Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATPClinical Pharmacology & Therapeutics, 2017
- Association of Kidney Function With AnemiaArchives of internal medicine (1960), 2002
- Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytesHepatology, 1990